Pyrimidine

Pyrimidine is one of the most versatile heterocycles in small-molecule drug discovery, present in the nucleobases cytosine, thymine, and uracil, making it a scaffold that has been central to medicinal chemistry since the earliest antimetabolite programmes. Since 2013, a rapidly expanding portfolio of FDA-approved drugs has highlighted pyrimidine as one of the most versatile and therapeutically valuable heteroaromatic scaffolds, with approvals spanning oncology, anti-infectives, immunology, neurological disorders, chronic pain, and metabolic diseases. The pyrimidine ring interacts with biological targets by forming robust hydrogen bonds via its two ring nitrogen atoms and acts as a bioisostere for phenyl and other aromatic π-systems, frequently improving the pharmacokinetic and pharmacodynamic properties of drug candidates across a broad range of target classes. The C-2, C-4, and C-5 positions offer regioselective handles for functionalisation via nucleophilic aromatic substitution, Buchwald-Hartwig amination, Suzuki coupling, and directed metalation. The 1,3-arrangement of the two nitrogen atoms creates a well-defined hydrogen-bond acceptor geometry that engages productively with kinase hinge regions, making pyrimidine the dominant hinge-binding motif in ATP-competitive kinase inhibitors.

Beyond kinase inhibition, the pyrimidine core appears in antivirals, antimalarials, antibiotics, and CNS agents, reflecting the breadth of its pharmacological utility, and the ring's moderate electron deficiency and metabolic stability make it a reliable tool for lead optimisation in programmes seeking improved oral bioavailability and reduced CYP inhibition. Imatinib (Gleevec, Novartis) is an FDA-approved first-in-class 2-phenylamino-pyrimidine derivative that selectively inhibits BCR-ABL, c-Kit, and PDGFR, first approved in 2001 for Philadelphia chromosome-positive chronic myelogenous leukaemia, representing a landmark validation of targeted kinase therapy and the pyrimidine scaffold in oncology. Lazertinib (Lazcluze, Janssen Biotech) is an FDA-approved oral third-generation EGFR tyrosine kinase inhibitor built around a 2-aminopyrimidine core, approved by the FDA on August 19, 2024, in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer harbouring EGFR exon 19 deletions or exon 21 L858R substitution mutations. The structure of lazertinib is distinguished among third-generation EGFR inhibitors by the combination of a hydrophobic phenyl group and a hydrophilic dimethylaminomethyl substituent on a pendant pyrazole attached at the C-4 position of the pyrimidine, with the pyrimidine serving as the central scaffold that positions the acrylamide warhead for irreversible covalent engagement with Cys797 of the EGFR kinase domain whilst the morpholine group at the C-2 position of the aniline improves aqueous solubility and pharmacokinetic profile relative to earlier-generation inhibitors.

Our range of Pyrimidines features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies.

Please examine a selection of Pyrimidines in our catalogue. The full range can be found using the substructure feature of our Search tools.